Stockreport

BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501

BioXcel Therapeutics, Inc.  (BTAI) 
Last bioxcel therapeutics, inc. earnings: 11/14 07:00 am Check Earnings Report
PDF Study aims to support BXCL501’s potential market expansion in chronic agitation disease conditions Topline results expected in the second quarter of 2020 NEW HAVEN, C [Read more]